Evidence map›Paper›PMID 30391138›Full record

ArticleClinical genitourinary cancer2019

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.

Anas M Saad, Mohamed M Gad, Muneer J Al-Husseini, Inas A Ruhban, Mohamad Bassam Sonbol, Thai H Ho

Abstract read
In one paragraph

Article in Clinical genitourinary cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Percutaneous cryoablation of kidney tumors after partial nephrectomy.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2024
    Article
  18. Article
  19. Incidence rates of bladder and kidney cancers among US military servicemen: comparison with the rates in the general US population.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2024
    Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anas M SaadFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed M GadFaculty of Medicine, Ain Shams University, Cairo, Egypt; Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH.
Muneer J Al-HusseiniFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Inas A RuhbanPathology department, Faculty of Medicine, Damascus University, Damascus, Syria.
Mohamad Bassam SonbolMayo Clinic Cancer Center, Phoenix, AZ.
Thai H HoMayo Clinic Cancer Center, Phoenix, AZ. Electronic address: ho.thai@mayo.edu.

Funding

Deciphering the interplay between H3K36 and DNA methylation in renal cancerR01CA224917 · NCI · MAYO CLINIC ROCHESTER · PI HO, THAI HUU, ROBERTSON, KEITH D · 2018 to 2022
$2.9M
NCI NIH HHS R01 CA224917
6 · The paper itself

Abstract

backgroundRenal-cell carcinoma (RCC) is one of the common malignancies in the United States. RCC incidence and mortality have been changing for many reasons. We performed a thorough investigation of incidence and mortality trends of RCC in the United States using the cell Surveillance, Epidemiology, and End Results (SEER) database. PATIENTS AND

methodsThe 13 SEER registries were accessed for RCC cases diagnosed between 1992 and 2015. Incidence and mortality were calculated by demographic and tumor characteristics. We calculated annual percentage changes of these rates. Rates were expressed as 100,000 person-years.

resultsA total of 104,584 RCC cases were reviewed, with 47,561 deaths. The overall incidence was 11.281 per 100,000 person-years. Incidence increased by 2.421% per year (95% confidence interval, 2.096, 2.747; P < .001) but later became stable since 2008. However, the incidence of clear-cell subtype continued to increase (1.449%; 95% confidence interval, 0.216, 2.697; P = .024). RCC overall mortality rates have been declining since 2001. However, mortality associated with distant RCC only started to decrease in 2012, with an annual percentage change of 18.270% (95% confidence interval, -28.775, -6.215; P = .006).

conclusionDespite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.

Indexed as

SEER ProgramAgedCarcinoma, Renal CellCohort StudiesFemaleFollow-Up StudiesHumansIncidenceKidney NeoplasmsMaleMortalityPrognosisSurvival RateTime FactorsUnited StatesKidney cancerMortalityRenal cell carcinomaSEER

Identifiers

PMID30391138
PMCPMC6348014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.